title: Hemodynamic Aging as the Consequence of Structural Changes Associated with Early Vascular Aging (EVA).
abstract: An increase in peripheral vascular resistance at rest is not routinely observed in healthy older persons, but often associated with increased stiffness of central elastic arteries, as hallmarks of aging effects on the vasculature, referred to as early vascular aging (EVA). In clinical practice, the increased arterial stiffness translates into increased brachial and central systolic blood pressure and corresponding pulse pressure in subjects above 50 years of age, as well as increased carotid-femoral pulse wave velocity (c-f PWV), a marker of arterial stiffness. A c-f PWV value ≥ 10 m/s is currently defined as a threshold for increased cardiovascular risk, based on consensus statement from 2012. Prevention and treatment strategies include a healthy lifestyle and the control of risk factors via appropriate drug therapy to achieve vascular protection related to EVA. New drugs are under development for vascular protection, for example the selective Angiotensin II (AT2) receptor agonist called compound 21. One target group for early intervention could be members of risk families including subjects with early onset cardiovascular disease.
authors.affiliation: Department of Clinical Sciences, Lund University, Skane University Hospital, Sweden.
authors.forename: Peter M
authors.initials: PM
authors.lastname: Nilsson
keywords: aging; arterial stiffness; blood pressure; cardiac; haemodynamic; vasculature
references.citation: Clin Sci (Lond). 2013 Mar;124(6):413-22
references.pmid: 22985469
references.citation: Circulation. 2006 Mar 7;113(9):1213-25
references.pmid: 16476843
references.citation: Hypertension. 2012 Feb;59(2):485-92
references.pmid: 22215717
references.citation: Lancet. 2010 Mar 13;375(9718):895-905
references.pmid: 20226988
references.citation: Lancet. 2012 Aug 11;380(9841):591-600
references.pmid: 22883508
references.citation: Vasc Med. 2013 Dec;18(6):340-6
references.pmid: 24292639
references.citation: Hypertension. 2009 Jul;54(1):3-10
references.pmid: 19487587
references.citation: Circulation. 2011 Apr 12;123(14):1545-51
references.pmid: 21444885
references.citation: J Hypertens. 2011 Jun;29(6):1034-42
references.pmid: 21519280
references.citation: J Hypertens. 2010 May;28(5):979-84
references.pmid: 20408258
references.citation: Diabetes Care. 2013 Aug;36 Suppl 2:S312-24
references.pmid: 23882065
references.citation: Acta Physiol Hung. 2012 Sep;99(3):271-8
references.pmid: 22982715
references.citation: J Hypertens. 2013 Aug;31(8):1517-26
references.pmid: 23743805
references.citation: J Hypertens. 2012 Mar;30(3):445-8
references.pmid: 22278144
references.citation: J Hypertens. 2013 Jul;31(7):1281-357
references.pmid: 23817082
references.citation: Circulation. 2009 Jan 20;119(2):243-50
references.pmid: 19118251
references.citation: Endocrinology. 2014 Mar;155(3):793-804
references.pmid: 24302627
references.citation: Hypertension. 2009 Sep;54(3):558-66
references.pmid: 19581507
references.citation: Hypertension. 2013 Jul;62(1):10-2
references.pmid: 23690344
references.citation: Blood Press. 2014 Feb;23(1):17-30
references.pmid: 23750722
references.citation: Diabetes Care. 2013 Mar;36(3):715-21
references.pmid: 23193205
references.citation: Vasc Med. 2010 Dec;15(6):461-8
references.pmid: 21056945
references.citation: J Hypertens. 2008 Jun;26(6):1049-57
references.pmid: 18475139
references.citation: J Hypertens. 2007 Jul;25(7):1421-6
references.pmid: 17563564
references.citation: Curr Opin Nephrol Hypertens. 2012 Mar;21(2):142-6
references.pmid: 22257799
references.citation: J Am Coll Cardiol. 2014 Feb 25;63(7):636-646
references.pmid: 24239664